Clinical study of rhIL-11 derivatives and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor

Objective To evaluate the efficacy and side effect of rhIL-11 derivatives and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. Methods A total of 63 malignant tumor patients with grade Ⅲ-Ⅳ thrombocytopenia( ≤50 × 109/L) after chemotherapy were collected and divided into treatment group and control group. At 24-48 hours after chemotherapy,the patients in treatment group received rhIL-11 derivatives 1. 5mg per day,while the patients in control group receivedrhIL-11 3 mg per day. The treatment would be ended when the platelets rose up to 100 × 109/L. The treatment time taken to get platelet rise up to 75 × 109/L or 100 × 109/L was compared between two groups. Adverse effects were observed during the treatment. Results There was a significant difference in the treatment time used to raise platelet up to 75 × 109/L between the treatment group( 6. 46 ± 2. 27) days and the control group( 6. 46 ± 2. 27) days( P 0. 01). There was also a significant difference in the treatment time used to raise platelet up to 100 × 109/L between the treatment group( 9. 07 ± 2. 45) days and the control group( 11.59 ±2.78) days( P 0.01). The incidences of adverse effects between two groups showed no significant difference( P 0. 05). Conclusion Bothe rhIL-11 derivatives and rhIL-11 are effective in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. The rhIL-11 derivatives has a more rapid effect to exhibit a slight advantage over rhIL-11.